Optimizing Antihypertensive Medication Selection in Community Hospitals: A Conceptual and Evidence-Based Approach (For Knowledge and Clinical Understanding, Not for Direct Prescription Ordering)
- Mayta
- Feb 25
- 12 min read
Updated: May 23
ขอขอบคุณ Pharmacist note สรุปทุกอย่างที่อ่านเจอ ที่ได้สรุปแนวทางการเลือกใช้ยาลดความดันเลือดในบริบทของโรงพยาบาลชุมชน (รพช.) ซึ่งมีข้อจำกัดด้านยาต่าง ๆ ออกมาได้อย่างชัดเจนและเข้าใจง่าย โดยเป็น การสรุปจากการทบทวนหลักฐานเชิงประจักษ์ (review evidence) และประสบการณ์จริง ไม่ใช่เพียงแค่ความคิดเห็นส่วนตัว หากต้องการอ้างอิงข้อมูลเชิงลึกเพิ่มเติม สามารถดูรายละเอียดจากแหล่งที่มาได้โดยตรง
🔗 อ่านสรุปฉบับเต็มได้ที่: โพสต์ต้นฉบับ 📷 ดูภาพประกอบจากโพสต์: ลิงก์รูปภาพ 📌 ติดตามเพจ Pharmacist note สรุปทุกอย่างที่อ่านเจอ ได้ที่: Facebook Page
ขอบคุณอีกครั้งที่แบ่งปันความรู้ให้กับทุกคนครับ! 🙏😊
1. Why Focus on Certain Antihypertensive Classes?
Modern guidelines (e.g., Thai Guidelines, JNC, ACC/AHA) highlight a few classes of medications that consistently show cardiovascular benefit—meaning they reduce not only blood pressure (BP) but also the risk of long-term complications such as heart attacks, strokes, and kidney failure. These “priority” classes are:
ACE Inhibitors (ACEi)
Angiotensin II Receptor Blockers (ARBs)
Calcium Channel Blockers (CCBs)
Thiazide/Thiazide-like Diuretics
Beta-Blockers (in certain indications)
These groups have strong evidence for improving outcomes, especially in patients with high cardiovascular risk (e.g., diabetes, chronic kidney disease, and heart failure).
Key Concepts
Renal Protection: ACEi and ARBs help reduce albuminuria and slow kidney disease progression.
Cardiovascular Risk Reduction: Thiazides, CCBs, and ACEi/ARBs each have large-scale trial evidence of reducing strokes, myocardial infarctions, and overall mortality.
Appropriate Use of Beta-Blockers: They are no longer first-line for uncomplicated hypertension but remain essential for those with ischemic heart disease, heart failure with reduced ejection fraction, or tachyarrhythmias.
2. Understanding Comorbidities & Contraindications
Comorbidities That Influence Drug Selection
Condition | Preferred First-Line Agents | Agents to Avoid |
Chronic Kidney Disease (CKD) + Proteinuria | ACEI/ARB (renal protective) | NSAIDs (worsen kidney function) |
Heart Failure (HFrEF) | ACEI/ARB + Beta-Blocker (Carvedilol, Metoprolol succinate) + Aldosterone Antagonist (Spironolactone) | CCBs (except Amlodipine), Alpha-Blockers |
Gout | ARB (Losartan may lower uric acid) | Thiazides (increase uric acid, may trigger gout flare) |
Asthma/COPD | CCB, ACEI/ARB (use with caution in cough-prone patients) | Non-selective Beta-Blockers (e.g., Propranolol, increase bronchospasm risk) |
Diabetes with Albuminuria | ACEI/ARB (kidney protection) | Beta-Blockers (may mask hypoglycemia) |
Pregnancy | Labetalol, Methyldopa, Nifedipine (ER), Hydralazine (for severe HTN) | ACEI/ARB (teratogenic risk) |
✅ Takeaway: Personalizing therapy ensures optimal BP control while reducing adverse effects. When selecting medications for hypertension, it is crucial to consider:
Patient’s Comorbidities (e.g., heart failure, CKD, diabetes, gout, pregnancy).
Potential Contraindications (e.g., angioedema history with ACEi, bilateral renal artery stenosis for ACEi/ARBs, pregnancy, severe asthma for beta-blockers).
Local Resource Availability (small or rural hospitals may have limited drug options).
Examples
CKD with proteinuria: Prefer ACEi or ARB for renal protection.
Asthma/COPD: Avoid or use caution with beta-blockers (especially non-selective).
Pregnancy: Avoid ACEi/ARBs (teratogenic risk). Labetalol, methyldopa, and nifedipine are safer options.
Hyperkalemia risk: Be cautious with ACEi/ARB, potassium-sparing diuretics.
Uncontrolled diabetes or gout: High-dose thiazides may affect glucose and uric acid levels.
3. Pharmacological Classes in Detail
💡 Most patients require more than one drug for effective BP control. Combining different mechanisms provides better BP reduction with fewer side effects.
Evidence-Based Combination Strategies
✔ ACEI/ARB + CCB → Highly effective, renal-friendly, balances vasodilation and RAAS inhibition.
✔ ACEI/ARB + Thiazide → Strong synergy, reduces fluid overload, avoids excessive vasodilation.
✔ CCB + Thiazide → Alternative when ACEI/ARB are contraindicated (e.g., pregnancy).
✔ Beta-Blocker + Thiazide → Historically used, but not first-line unless compelling indications (e.g., post-MI, HF).
⚠ Avoid Unsafe Combinations:
🚫 ACEI + ARB → No added benefit, high risk of hyperkalemia & kidney injury.
🚫 Beta-Blocker + Non-DHP CCB (Verapamil, Diltiazem) → Risk of bradycardia & heart block.
Below is a conceptual overview of the main antihypertensive drug classes commonly found in smaller hospitals (รพช., or community hospitals in Thailand) and other limited-resource settings:
3.1 ACE Inhibitors
Examples: Enalapril, Captopril
Main Benefits:
Renoprotective: Reduce albuminuria, slow progression of CKD.
Cardiovascular risk reduction: Beneficial in heart failure, left ventricular hypertrophy, diabetes, and post-MI.
Mechanism: Blocks conversion of angiotensin I to angiotensin II → reduces vasoconstriction, decreases aldosterone, lowers BP, offers renal protection by reducing intraglomerular pressure.
Common Side Effects:
Cough (due to bradykinin accumulation; not dose-dependent).
Hyperkalemia (due to reduced aldosterone).
Key Precautions and Contraindications:
Pregnancy, bilateral renal artery stenosis, prior angioedema to ACEi.
If baseline sCr is >3–5 mg/dL, initiation is risky due to possible acute kidney injury (start with low doses if necessary).
Monitoring:
Check serum creatinine and potassium at 2–4 weeks after initiation or dose changes.
Stop if eGFR drops >25% or sCr rises >30% from baseline (after ruling out other causes like NSAIDs, volume depletion).
3.2 Angiotensin II Receptor Blockers (ARBs)
Examples: Losartan, Valsartan
Advantages Over ACEi:
Similar renal and cardiovascular benefits, but less cough (as they do not increase bradykinin).
Precautions & Contraindications:
Same as ACEi: pregnancy, bilateral renal artery stenosis, hyperkalemia.
No ACEi + ARB Dual Therapy
Combining them raises the risk of hyperkalemia and kidney injury without additional cardiovascular benefit.
3.3 Calcium Channel Blockers (CCBs)
Dihydropyridines (DHPs): Amlodipine, Nifedipine
Mechanism: Preferentially dilate peripheral arterioles, reducing afterload.
Clinical Effects: Potent BP-lowering, minimal negative inotropic effect (amlodipine is generally safe in heart failure).
Side Effects: Peripheral edema, flushing, reflex tachycardia (especially with short-acting agents).
Non-DHPs: Verapamil, Diltiazem
Often used for arrhythmias (rate control in atrial fibrillation), but can depress cardiac contractility and slow conduction.
Avoid in HFrEF or when high risk of bradycardia/AV block.
3.4 Thiazide and Thiazide-like Diuretics
Examples: Hydrochlorothiazide (HCTZ), Chlorthalidone, Indapamide
Mechanism: Inhibit sodium reabsorption in the distal tubule, reducing plasma volume and peripheral vascular resistance.
Common Side Effects:
Electrolyte disturbances: Hypokalemia, hypomagnesemia, hyponatremia
Hyperglycemia, Hyperuricemia, Hyperlipidemia, Hypercalcemia (the mnemonic “HyperGLUC”)
Renal Function Considerations:
Less effective if eGFR <30 ml/min (loop diuretics may be required).
Practical Tip: Start with lower doses (e.g., 12.5–25 mg HCTZ) to reduce metabolic side effects.
3.5 Beta-Blockers
Examples: Atenolol (β1-selective), Propranolol (non-selective)
Primary Indications in HTN:
Heart failure with reduced EF, post-myocardial infarction, tachyarrhythmias, angina.
Not typically first-line in “uncomplicated” hypertension unless specific indications exist.
Side Effects:
Bradycardia, fatigue, bronchospasm (especially non-selective in asthmatics), can mask hypoglycemia in diabetes.
Precautions:
Asthma/COPD: Non-selective beta-blockers may worsen bronchoconstriction.
DM: May hide symptoms of hypoglycemia (e.g., palpitations).
3.6 Potassium-Sparing Diuretics
Examples: Spironolactone, Amiloride (often combined with HCTZ in “Moduretic”)
Mechanism: Reduce potassium excretion at the collecting tubules (Spironolactone blocks aldosterone; Amiloride blocks sodium channels).
Clinical Use:
Spironolactone is key in resistant hypertension and heart failure (aldosterone blockade).
Good as add-on therapy when hypokalemia is an issue or in aldosterone-excess states.
Side Effects:
Hyperkalemia, gynecomastia (particularly with spironolactone).
Monitoring:
Potassium and renal function, especially if used with ACEi/ARB or in advanced CKD.
3.7 Alpha-1 Blockers
Example: Doxazosin
Use in HTN:
Typically not first-line unless patient has coexisting benign prostatic hyperplasia (BPH).
Often an add-on agent in resistant HTN if others are contraindicated.
Side Effects:
Orthostatic hypotension, possible reflex tachycardia.
Can worsen outcomes in heart failure if not carefully combined (fluid retention).
3.8 Direct Vasodilators
Example: Hydralazine
Mechanism: Direct arteriolar dilation → lowers afterload.
Drawbacks:
Reflex sympathetic activation (tachycardia, palpitations).
Can cause headache, flushing, and, with long-term use, lupus-like syndrome.
Niche Uses:
Combined with nitrates in heart failure for specific populations or in pregnancy-related HTN management (e.g., IV hydralazine).
Often a last-line agent when simpler combinations fail or are contraindicated.
4. Conceptual Framework for Medication Selection Laboratory Monitoring Needs by Drug Class
Drug Class | Key Labs to Monitor | When to Check |
ACEI/ARB | Creatinine, Potassium | 2-4 weeks after starting |
Thiazide Diuretics | Sodium, Potassium, Uric Acid | Periodically (every 3-6 months) |
Beta-Blockers | Heart Rate, Glucose (diabetics) | Monitor HR regularly |
CCBs | Ankle Swelling (DHP), Heart Rate (Non-DHP) | Clinical monitoring |
Spironolactone (Aldosterone Antagonist) | Potassium, Creatinine | 2 weeks after starting, then every 3-6 months |
💡 Practical Tip:
✔ ACEI/ARB + Spironolactone? → Check potassium frequently (risk of hyperkalemia).
✔ Thiazide use in elderly? → Monitor sodium levels (risk of hyponatremia).
✔ Beta-Blockers in diabetics? → Watch for masked hypoglycemia symptoms.
Rather than simply memorizing an algorithm for medication ordering, clinicians should understand why certain classes come first and how to tailor regimens based on patient-specific characteristics. Below are key guiding principles:
Start with Agents Proven to Reduce CV Events
If the patient has kidney involvement (albuminuria), an ACEi or ARB is generally first choice.
If no renal concerns, any of the top-tier classes (ACEi/ARB, CCB, or Thiazide) can be started.
Account for Comorbidities
Heart failure? Prefer ACEi/ARB, beta-blocker, possibly aldosterone antagonists.
Gout? High-dose thiazides can exacerbate hyperuricemia.
COPD/Asthma? Avoid non-selective beta-blockers or use caution.
Combine Different Mechanisms
Most patients require ≥2 drugs for optimal BP control.
A typical combination is ACEi/ARB + CCB or ACEi/ARB + Thiazide.
Monitor Labs & Clinical Status
Renal function (serum creatinine, eGFR) is critical for dosing adjustments (e.g., enalapril, atenolol, spironolactone).
Potassium checks are essential if using ACEi/ARB or potassium-sparing diuretics.
Electrolyte profile for patients on thiazides/loop diuretics.
Adapt to Resource Constraints
Some community hospitals may only stock a handful of options (e.g., Enalapril, Losartan, Amlodipine, HCTZ, Atenolol, Spironolactone, Hydralazine). Understanding each agent’s mechanism, side-effect profile, and dose adjustment is crucial.
1. Start with Agents Proven to Reduce Cardiovascular Events
1. Start with Agents Proven to Reduce Cardiovascular Events
Core Rationale: Large-scale clinical trials consistently show that certain drug classes—ACE Inhibitors (ACEI), ARBs, Calcium Channel Blockers (CCBs), and Thiazide/Thiazide-like Diuretics—significantly reduce stroke, myocardial infarction, and cardiovascular mortality. Beta-blockers retain a pivotal role for specific conditions (e.g., post-MI, heart failure with reduced EF, tachyarrhythmias), but they are not always a top choice for uncomplicated hypertension.
1.1 If the Patient Has Kidney Involvement (Albuminuria)
Why ACEI or ARB First?
Mechanism: Both reduce intraglomerular pressure, slow kidney damage, and help reduce albuminuria.
Practical Points from the Algorithm (Green Box):
Enalapril (ACEI): Start at 5–20 mg/day (max 40 mg/day), adjusting for CKD (e.g., 2.5 mg/day in GFR 30–60 ml/min). Monitor for cough and hyperkalemia.
Losartan (ARB): Typically 50 mg/day (max 100 mg/day), no major dose adjustment for renal function, but still monitor potassium and renal function.
1.2 If the Patient Has No Renal Concerns (No Albuminuria)
Any of the “green box” classes—ACEI/ARB, CCB, or Thiazide—can be a solid initial choice.
In Practice: Many guidelines (including Thai HTN guidelines) will choose 1 or 2 of these classes based on side-effect profiles and patient factors.
Specifics from the Algorithm (Orange Box for those without albuminuria):
CCB (e.g., Amlodipine 5–10 mg/day): Highly effective in lowering BP; watch for peripheral edema and flushing.
Thiazide (e.g., HCTZ 25 mg/day): Good evidence base; watch out for electrolyte imbalances (hypokalemia, hyponatremia) and potential issues in gout or uncontrolled diabetes.
2. Account for Comorbidities
2. Account for Comorbidities
Different conditions heavily influence the preferred drug choice:
Heart Failure (particularly reduced EF)
ACEI/ARB + Beta-blocker (often carvedilol or metoprolol succinate, but in smaller hospitals, atenolol might be used if that’s the available β1-selective option).
If patients remain hypertensive, an aldosterone antagonist (e.g., spironolactone) may be added, unless limited by renal function or hyperkalemia.
Hydralazine + nitrates are used if ACEI/ARB is contraindicated or not tolerated, particularly in certain populations.
Gout
High-dose thiazides can exacerbate hyperuricemia and trigger gout flare-ups. In these patients, consider either ARB (some data suggests losartan may slightly reduce uric acid) or a smaller dose of thiazide if absolutely needed.
COPD/Asthma
Non-selective beta-blockers (e.g., propranolol) can worsen bronchospasm. If a beta-blocker is indicated for a compelling reason (e.g., heart failure, ischemic heart disease), use a β1-selective agent like atenolol (still monitor respiratory status).
Pregnancy
Avoid ACEI/ARB. Safer alternatives include labetalol, methyldopa, extended-release nifedipine, or short-term hydralazine (especially IV in severe cases).
3. Combine Different Mechanisms
3. Combine Different Mechanisms
Reasoning: Most patients eventually need at least two antihypertensive agents to achieve target BP (<130/80 mmHg or as locally recommended). Combining drugs with complementary mechanisms often provides more robust BP reduction and helps avoid hitting the side-effect ceiling of one agent.
Typical Combinations
ACEI/ARB + CCB: Good synergy; the RAAS blocker helps prevent fluid retention, while the CCB focuses on vasodilation.
ACEI/ARB + Thiazide: Another strong combination; the diuretic counters volume overload and RAAS activation, while the ACEI/ARB protects the kidneys and lowers peripheral resistance.
Avoid “Duplicate” Mechanisms
ACEI + ARB is contraindicated due to increased risk of hyperkalemia and renal impairment without extra cardiovascular benefit.
Algorithmic Application
After starting a first-line agent, if BP is still not controlled, add a second-line or second “first-line” agent from a different class (e.g., if on ACEI already, add a CCB or Thiazide next).
4. Monitor Labs & Clinical Status
Effective and safe treatment hinges on re-evaluating the patient’s response and detecting potential side effects promptly.
Renal Function (CrCl, eGFR, Serum Creatinine)
ACEI/ARBs can cause a slight rise in creatinine initially, but a >30% jump may indicate an acute kidney injury or bilateral renal artery stenosis.
Thiazides are less effective if CrCl <10 ml/min; consider switching to loop diuretics for advanced CKD.
Serum Potassium
Critical if using ACEI/ARB or potassium-sparing diuretics (e.g., spironolactone, amiloride).
Hyperkalemia risk escalates if these drugs are combined, or if renal function deteriorates.
Electrolyte Profile
Thiazides can cause hyponatremia, hypokalemia, and sometimes hypercalcemia.
Beta-blockers do not typically require routine electrolyte checks, but watch for metabolic issues in diabetics.
Clinical Side Effects
Orthostatic Hypotension with alpha-blockers (e.g., doxazosin).
Reflex Tachycardia with direct vasodilators (hydralazine).
Peripheral Edema with amlodipine or other DHP-CCBs.
5. Adapt to Resource Constraints
5. Adapt to Resource Constraints
Community hospitals or smaller facilities may have limited formularies, often including:
Enalapril (ACEI), Losartan (ARB)
Amlodipine (CCB)
HCTZ (thiazide)
Atenolol (beta-blocker)
Spironolactone (potassium-sparing diuretic)
Hydralazine (direct vasodilator)
5.1 Applying the Algorithm to Limited Choices
Green Box (Preferred for CKD/Albuminuria): ACEI (Enalapril) or ARB (Losartan).
Dose adjustments for Enalapril in Stage 3–4 CKD are crucial. Losartan typically does not require a dose adjustment but still needs serum creatinine and potassium monitoring.
Orange Box (For HTN without Albuminuria):
Amlodipine 5–10 mg/day: Minimal lab monitoring, good BP reduction.
HCTZ 25 mg/day: Effective at moderate doses (25–50 mg/day). Check electrolytes.
Second-Line When BP Remains High:
Spironolactone or Moduretic (Amiloride+HCTZ) for resistant HTN or to correct hypokalemia from thiazides; watch for hyperkalemia.
Beta-blocker (Atenolol): Especially in patients with ischemic heart disease.
Alpha-blocker (Doxazosin): If BPH present or as a last-line add-on in resistant HTN.
Third-Line for Further Uncontrolled Cases:
Hydralazine: Titrate carefully, watch for reflex tachycardia, flushing. Combined with a beta-blocker or diuretic if needed.
5.2 Real-World Tips
Dose Titration: Start low, especially in the elderly or those with advanced CKD, then go slow.
Periodic Lab Checks: Even if resources are limited, try to obtain at least baseline and follow-up creatinine/potassium levels after initiating or escalating RAAS blockers or potassium-sparing agents.
Patient Education: If labs or visits are not frequent, thorough counseling about signs of hypotension, hyperkalemia (e.g., muscle weakness, arrhythmias), or adverse effects is critical.
Putting It All Together: Deepening the Conceptual Understanding
Putting It All Together: Deepening the Conceptual Understanding
Start with the “Green Box” if the patient shows renal involvement (albuminuria)—i.e., ACEI or ARB are generally first-line and provide both BP control and renal protection.
If there's no albuminuria, any top-tier class (ACEI/ARB, CCB, or Thiazide) is appropriate.
Escalate to combination therapy if BP remains above target, typically mixing classes that complement one another (e.g., RAAS blockade with a diuretic or CCB).
Monitor to detect changes in kidney function or electrolytes, especially when using RAAS blockers or diuretics.
Adapt to your hospital's drug supply and your patient’s unique comorbidities, side-effect risk, and lab accessibility.
Refine therapy iteratively. If three or more drugs are needed (resistant HTN), consider adding spironolactone or other second-line agents, ensuring that you avoid dangerous combinations (like ACEI + ARB) or unmonitored hyperkalemia.
By merging these conceptual pillars with the specific details from the algorithm (doses, side effects, renal dose adjustments), clinicians can design safe, effective, and personalized hypertension regimens—whether in a well-resourced city hospital or a small community setting.
5. Monitoring & Follow-Up: The Conceptual Importance
Clinical Assessment
Reassess BP levels in 2–4 weeks after any medication initiation or dose change.
Evaluate patient tolerance, side effects (like orthostatic hypotension, cough, or pedal edema).
Laboratory Monitoring
ACEi/ARB: Check sCr and K+ at baseline and 2–4 weeks to catch acute kidney injury or hyperkalemia.
Diuretics: Check electrolytes (Na, K, Mg), especially in older adults prone to electrolyte imbalances.
Beta-Blockers: May need to check heart rate, watch for bradycardia symptoms, consider glycemic control in diabetics.
Lifestyle & Non-Pharmacologic Measures
Always reinforce salt restriction, weight control, regular exercise, and moderation of alcohol.
These significantly enhance the efficacy of pharmacologic therapy and may reduce the number or doses of medications needed.
6. Practical Pearls in Resource-Limited Settings
Maximize Agent(s) Before Adding More
Titrate to a moderate or near-maximally tolerated dose while monitoring for side effects.
Then add a second agent from a different class if BP remains above target.
Avoid Duplicate Mechanisms
Do not combine ACEi + ARB (risk of hyperkalemia and renal harm, no proven benefit).
Use caution if combining multiple potassium-affecting drugs (e.g., ACEi + spironolactone).
Look for Low-Lab Monitoring Options
In certain scenarios (e.g., extremely limited lab access), some clinicians might choose a beta-blocker + CCB + hydralazine path, but always weigh the risk of missing metabolic derangements vs. short-term practicality.
Assess Patient Literacy & Compliance
Use combination pills where possible to reduce pill burden (e.g., Losartan/HCTZ).
Provide clear counseling about potential side effects (cough, dizziness, edema) to improve adherence.
7. Considerations for Community Hospitals (รพช.) with Limited Drug Availability
Many community hospitals have a restricted formulary with only a few key antihypertensives. The following adaptations can help optimize treatment:
Commonly Available Antihypertensive Medications in รพช.
ACEI: Enalapril
ARB: Losartan
CCB: Amlodipine
Thiazide Diuretic: Hydrochlorothiazide (HCTZ)
Beta-Blocker: Atenolol
Aldosterone Antagonist: Spironolactone
Vasodilator (if needed): Hydralazine
How to Optimize Hypertension Management in รพช.
✔ Start with ACEI/ARB + CCB if available (best BP-lowering, renal protection).
✔ If diuretics are necessary, use low-dose Thiazides (avoid hypokalemia).
✔ Beta-Blockers should be reserved for specific indications (e.g., heart disease, post-MI).
✔ Use Hydralazine only if other options fail (e.g., resistant HTN).
✔ Monitor renal function, potassium, and electrolytes whenever possible.
💡 Real-World Tip: If frequent lab monitoring is not possible, consider starting with a CCB-based regimen (Amlodipine), which requires minimal lab checks compared to ACEI/ARBs.
8. Putting It All Together: A Knowledge-Driven Approach
Initial Thought Process: “Does the patient have kidney disease or albuminuria?” → If yes, strongly consider ACEi/ARB.
Next Layers: “Any other comorbidities?” → Heart failure? Angina? Diabetes with microalbuminuria? Gout?
Add-On Decisions: “Is BP controlled with a single drug at moderate dose?” → If not, add a complementary class (e.g., if started with ARB, consider adding a thiazide or CCB).
Refine Therapy Over Time: Monitor labs (potassium, renal function) and side effects. Adjust or switch as needed.
By framing medication choices in conceptual and pathophysiological terms, you’re equipped to adapt to varied clinical scenarios, even when guidelines differ slightly, or the drug formulary is limited.
9. Important Disclaimers & References
This resource is designed to provide conceptual knowledge rather than explicit prescription orders.
Always refer to official or local guidelines (e.g., Thai Hypertension Guidelines 2019, Clinical Practice Recommendation for CKD 2022, ACC/AHA, JNC 8), hospital protocols, and updated evidence when finalizing treatment plans.
Non-pharmacological interventions remain an integral part of HTN management. Encourage healthy diet, weight control, and routine physical activity for optimal outcomes.
Key References
2019 Thai Guidelines on the Treatment of Hypertension
Clinical Practice Recommendation for the Evaluation and Management of Chronic Kidney Disease in Adults 2022 (Revised Edition)
UpToDate – Comprehensive clinical decision support for HTN
Major International Guidelines – ACC/AHA, ESC/ESH, JNC 8
Conclusion
A knowledge-based, conceptual approach to hypertension management ensures that clinicians:
Prioritize drugs with the greatest evidence for cardiovascular and renal protection.
Tailor therapy to individual patient factors—comorbidities, kidney function, side effects, and local drug availability.
Understand mechanisms and monitoring requirements, ensuring both safe and effective BP control over time.
Comments